EQHealthcare · BiotechnologyThe 9 Wall Street analysts covering Equillium, Inc. hold a median 12-month price target of $7 — +231.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Equillium, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (84): Sales and profits are climbing, and climbing faster than before.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EQ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +231.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Sept 2026 | Roth Capital | Reiterates | Buy | $12 |
| 13 July 2026 | Piper Sandler | Initiates | Overweight | $20 |
| 13 July 2026 | Piper Sandler | Initiates | Overweight | — |
| 2 June 2026 | Roth Capital | Reiterates | Buy | — |
| 28 May 2026 | Leerink Partners | Upgrade | Outperform | — |
| 28 May 2026 | Roth Capital | Reiterates | Buy | — |
| 17 Apr 2026 | Roth Capital | Reiterates | Buy | — |
| 16 Apr 2026 | B. Riley Securities | Initiates | Buy | — |
| 14 Apr 2026 | Raymond James | Initiates | Strong Buy | — |
| 13 Mar 2026 | Roth Capital | Initiates | Buy | — |
| 28 Mar 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 1 Nov 2024 | Jones Trading | Downgrade | Hold | — |
| 19 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Dec 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 14 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EQ appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Equillium, Inc. returned +6.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 40% of US stocks
Cheaper than 77% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Equillium, Inc. has a market value of $133.8M and an enterprise value of $77.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$18.0M.
Diluted earnings per share, trailing twelve months: $−0.20.
Free cash flow in the twelve months to 30 June 2026: −$20.1M.
Trailing P/E: −5.4×; forward P/E: −9.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Equillium, Inc. employs 14 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Equillium, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Equillium announced that management will participate in upcoming investor conferences, including a fireside chat and 1x1 meetings at the Cantor Global Healthcare Conference 2026 on September 9, 2026. A webcast link was provided for the event.
Why it matters — Participation in investor conferences gives management a platform to present Equillium's pipeline and developments to the investment community.
Equillium reported Q2 2026 financial results and corporate updates, including the planned initiation of a Phase 1 proof-of-mechanism study of EQ504 in Q4 2026 with data expected approximately six months later. The company reported $57.2 million in cash and cash equivalents expected to fund operations into 2029.
Why it matters — EQ watchers would care because the upcoming EQ504 Phase 1 study timeline provides a key near-term catalyst for the company's lead pipeline candidate.
The 9 Wall Street analysts covering Equillium, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Equillium, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Equillium, Inc. 43 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Equillium, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +231.8% from the last close, and Ticker Nerd's factor model ranks Equillium, Inc. 43 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Equillium, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EQ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $20 over the next 12 months.
Equillium, Inc. returned +6.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need.
The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Equillium to Participate in Upcoming Investor Conferences". Equillium announced that management will participate in upcoming investor conferences, including a fireside chat and 1x1 meetings at the Cantor Global Healthcare Conference 2026 on September 9, 2026. A webcast link was provided for the event.
Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases. The company’s work spans immuno-inflammatory areas across transplant science, gastroenterology, rheumatology, dermatology, oncology, and related specialty care segments. Equillium Inc. operates as a research-driven biopharmaceutical business, advancing novel therapeutic candidates through clinical development and strategic collaborations to address complex diseases where existing treatment options remain limited. Headquartered in La Jolla, California, Equillium Inc. plays a focused role in the biotechnology market as a developer of targeted immune-modulating medicines.
CEO Mr. Bruce Steel · 14 employees · United States · https://www.equilliumbio.com
